Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 2:10:1070420.
doi: 10.3389/fmed.2023.1070420. eCollection 2023.

Hepatitis B virus and hepatitis D virus infection in women with or at risk for HIV infection in the United States

Ilona Argirion  1 , Parag Mahale  1 , Ruth M Pfeiffer  2 , Ping Liu  3 , Adaora A Adimora  4 , Matthew J Akiyama  5   6 , Hector H Bolivar  7 , Audrey French  8   9 , Michael Plankey  10 , Jennifer C Price  11 , Aadia Rana  12 , Anandi Sheth  13   14 , Jill Koshiol  1 , Eric C Seaberg  15 , Mark H Kuniholm  16 , Jeffrey Glenn  3 , Thomas R O'Brien  1
Affiliations

Hepatitis B virus and hepatitis D virus infection in women with or at risk for HIV infection in the United States

Ilona Argirion et al. Front Med (Lausanne). .

Abstract

Hepatitis D virus (HDV) requires co-infection with hepatitis B virus (HBV). Human immunodeficiency virus (HIV) shares transmission routes with these viruses. Among 4,932 US women infected with or at-risk for HIV during 1994-2015, HBV surface antigen (HBsAg) positivity was more common in women with HIV (2.8% vs. 1.2%; p = 0.001); HDV was more common among participants enrolled during 2013-2015 (p = 0.0004) and those with resolved rather than active hepatitis C (1.9% vs. 0.5%; p = 0.02). Among HBsAg-positive women (n = 117), HDV antibody prevalence was 22% and did not vary by HIV status; HDV infection was associated with the presence of advanced fibrosis/cirrhosis at enrollment (adjusted odds ratio, 5.70; 95% confidence interval, 1.46-22.29). Our results demonstrate the importance of HDV testing in HBV-infected US women.

Keywords: anti-HDV; epidemiology; hepatitis B virus; hepatitis C virus; hepatitis D virus; persons who injected drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011-2016. Clin Infect Dis. (2019) 69:709–12. doi: 10.1093/cid/ciz001, PMID: - DOI - PMC - PubMed
    1. Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, et al. . Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in N orthern C alifornia. J Gastroenterol Hepatol. (2013) 28:1521–5. doi: 10.1111/jgh.12217 - DOI - PubMed
    1. Fernández-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. . Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. (2014) 58:1549–1553. doi: 10.1093/cid/ciu167, PMID: - DOI - PubMed
    1. Ferrante ND, Lo Re V. Epidemiology, natural history, and treatment of Hepatitis Delta virus infection in HIV/hepatitis B virus coinfection. Curr HIV/AIDS Rep. (2020) 17:405–14. doi: 10.1007/s11904-020-00508-z, PMID: - DOI - PMC - PubMed
    1. Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. (2021) 70:1782–94. doi: 10.1136/gutjnl-2020-323888, PMID: - DOI - PMC - PubMed